Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02500849 · ClinicalTrials.gov registry record · Phase 1

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

A Phase 1 study of HIV, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
5
Study locations

NCT02500849: Active Phase 1 study of HIV, sponsored by City of Hope Medical Center.

NCT02500849 is a Phase 1 study of HIV that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 12 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02500849, a Phase 1 study of HIV, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
5
Study locations

Study Summary

The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

Conditions Studied

HIV

Interventions

  • GENETIC SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Study Locations (5)

California

  • City of Hope Medical Center - Duarte
  • UCLA CARE Center - Los Angeles
  • Mills Clinical Research - Los Angeles
  • Quest Clinical Research - San Francisco

Connecticut

  • Circle CARE Center, LLC - Norwalk

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-03-10
Est. Completion 2026-08-24
Phase Phase 1
City of Hope Medical Center

582 total trials

What the registry record for NCT02500849 still lists

NCT02500849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which SB-728mR-HSPC Infusion 3 days following busulfan conditioning is the first listed.

NCT02500849 lists 5 locations in 2 states (California, Connecticut).

Frequently Asked Questions

What is clinical trial NCT02500849 about?

NCT02500849 is a clinical study titled "Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients". The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.

What is the current status of trial NCT02500849?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-03-10. Estimated completion is 2026-08-24.

What conditions does trial NCT02500849 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02500849?

The interventions under investigation include: SB-728mR-HSPC Infusion 3 days following busulfan conditioning (GENETIC).

Who is sponsoring clinical trial NCT02500849?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02500849 being conducted?

This trial has 5 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02500849's enrollment target sits among peer trials

12 293rd of 303 higher than 7 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02500849, the US trial registry maintained by the National Library of Medicine. NCT02500849 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.